real-time news and commentary for investors
Thursday, Oct 24
Rigel updates pipeline, nixes one indication for R333
- Rigel Pharmaceuticals (RIGL -1.4%) gives investors a pipeline update.
- R333 is out (at least as a potential treatment for active skin lesions in DLE patients) after the drug missed its primary endpoint in a Phase 2 study.
- RIGL will initiate two pivotal studies of fostamatinib for ITP in H1 2014. Investors should expect top line data in 2015. (PR)